Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | PARP1 | P09874 | 6/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TNKS | O95271 | 1/20 | 0.53 |
| ▸ | GPR3 | P46089 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | ALPG | P10696 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30273084 | 1.00 | MEN1 (0.66) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL30293232 | 0.98 | MEN1 (0.64) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL30158836 | 0.96 | HSD17B10 (0.61) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL25911476 | 0.96 | HSD17B10 (0.61) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL14355018 | 0.80 | KDM4E (0.57) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL4021839 | 0.79 | HSD17B10 (1.00) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL29666273 | 0.79 | HSD17B10 (1.00) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL6643819 | 0.79 | HPGD (0.53) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL2269424 | 0.79 | KDM4E (0.63) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL7251361 | 0.78 | PARP1 (0.65) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| WO-2023134647-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 优领医药科技(香港)有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| EP-3880660-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| CN-113166065-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020102096-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102096-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| EP-1937640-A2 | 1,2,3,5-TETRAHYDRO-CYCLOPENTAL[C]QUINOLIN-4-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1129077-B9 | FLUORINATED 3,4-DIHYDROQUINOLINE DERIVATIVES USED AS NOS INHIBITORS | SCHERING AG (DE) | 2005-07-20 | — | — | EP | disclosed |
| EP-1129077-B1 | FLUORINATED 3,4-DIHYDROQUINOLINE DERIVATIVES USED AS NOS INHIBITORS | SCHERING AG (DE) | 2005-04-20 | — | — | EP | disclosed |
| EP-1054869-B1 | 3,4-DIHYDROQUINOLINE DERIVATIVES AS NITROGEN MONOXIDE SYNTHASE (NOS) INHIBITORS | SCHERING AG (DE) | 2004-09-22 | — | — | EP | disclosed |
| US-6579883-B1 | Nitrogen monoxide synthases; 4-amino-8-bromo-3a-fluoro-2,3,3a,9b-tetrahydro-1H-cyclopenta (c) quinoline; neurodegenerative, autoimmune, cardiovascular diseases | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-17 | — | — | US | disclosed |
| US-20030105102-A1 | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity | GUILFORD PHARMACEUTICALS INC. | 2003-06-05 | — | — | US | disclosed |
| US-6391887-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-05-21 | — | — | US | disclosed |
| US-20020022636-A1 | OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY | GUILFORD PHARMACEUTICALS INC. | 2002-02-21 | — | — | US | disclosed |
| US-6235748-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2001-05-22 | — | — | US | disclosed |
| EP-1009739-A2 | OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999011624-A1 | OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022636-A1 | OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY | PARP2, PARP1, PARP3 | MEN1 4123/4885KMT2A 1819/4885HSD17B10 776/4885 |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MEN1 3390/4885KMT2A 4441/4885HSD17B10 1086/4885 |
| US-20030105102-A1 | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity | PARP1, PARP3, PARP2 | MEN1 3911/4885KMT2A 1919/4885HSD17B10 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.